

**Have you, or has someone
you love, been previously
treated for metastatic
colorectal cancer?**

If so, you or your loved one may be eligible to participate in a nationwide research study of an investigational drug called panitumumab given along with chemotherapy for the treatment of metastatic colorectal cancer. This study is designed to test if an intervention on the skin rash often seen with panitumumab, and similar drugs, affects its course. This study is called STEPP (Skin Toxicity Evaluation Protocol with Panitumumab) and is being sponsored by Amgen.

Participants in the study will:

- Gain access to a research treatment that may or may not be as effective as standard therapy
- Help other patients by advancing knowledge of the treatment of colorectal cancer

To learn if you may be eligible to enroll, **CALL
TODAY AND ASK ABOUT THE STEPP TRIAL.**

Or visit

AMGEN[®]